TP53 and glioblastoma: Since GBM pathogenesis and prognosis are strictly related to a number of well-established mutations, transgenic/knockout mice were developed to investigate the effects concerning the activation of oncogenic signaling pathways (EGFR, RAS, PI3K) and the loss of GBM oncosuppressors (TP53, PTEN) [20,21].